PCSK9 downregulators (Pfizer)

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug NamePCSK9 downregulators (Pfizer)

Drug Alias Namesmall molecule inhibitors of the PCSK9-LDLR interaction (Pfizer)small molecule proprotein convertase subtilisin/kexin type 9 modulators (Pfizer)PCSK9 (Pfizer)

ClassificationSmall molecules

Mechanisms of ActionLDL receptor modulatorsProprotein convertase subtilisin kexin type 9 inhibitors

TargetsProprotein convertase subtilisin kexin type 9LDL receptor

Therapy Area/IndicationsHypercholesterolemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsHypercholesterolemia

Other Information

ATC CodeN/A